effectiveness of glp 1 GLP-1 anti-obesity medicines remain too expensive Pharmacological treatment for patients with

This is mainly because of the reported weight loss While GLP-1 medications Zepbound and This rapid increase in users of GLP-1 drugs has caused Now, a new study published in Annals of Internal Medicine , reports that among the approximately 1 million new GLP-1 medication users identified between 2011 to 2023, there was a twofold increase in GLP-1 medication users who do not have type 2 diabetes but do have a body mass index (BMI) of 30 killograms per square meter (kg/m 2 ) or greater, and in people with a BMI of 27 to 30 kg/m 2 and an obesity-related The researchers also found that the proportion of users of GLP-1 medications without FDA-approved indications rose from 0.21% in 2019 to 0.37% in 2023

Oxford: Academic Press

However, it is not recommended for pregnant or lactating women, or those with certain medical conditions

Liposome as a delivery system for the treatment of biofilm-mediated infections

Why Patients Switch to Chronos Weight loss should feel personal, supportive, and rooted in real healthcare

Facilitates the metabolism of long-chain fatty acids